SMT201800018T1 - Animali umanizzati con il-4 e il4r alfa - Google Patents

Animali umanizzati con il-4 e il4r alfa

Info

Publication number
SMT201800018T1
SMT201800018T1 SM20180018T SMT201800018T SMT201800018T1 SM T201800018 T1 SMT201800018 T1 SM T201800018T1 SM 20180018 T SM20180018 T SM 20180018T SM T201800018 T SMT201800018 T SM T201800018T SM T201800018 T1 SMT201800018 T1 SM T201800018T1
Authority
SM
San Marino
Prior art keywords
humanized
animals
alpha
alpha animals
Prior art date
Application number
SM20180018T
Other languages
English (en)
Italian (it)
Inventor
Sean Stevens
Andrew J Murphy
Li-Hsien Wang
Yingzi Xue
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SMT201800018T1 publication Critical patent/SMT201800018T1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/20—Animal model comprising regulated expression system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0368—Animal model for inflammation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0393—Animal model comprising a reporter system for screening tests

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Environmental Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
SM20180018T 2014-05-07 2015-05-07 Animali umanizzati con il-4 e il4r alfa SMT201800018T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461989757P 2014-05-07 2014-05-07
EP15727106.5A EP3027015B1 (en) 2014-05-07 2015-05-07 Humanized il-4 and il-4r alpha animals
PCT/US2015/029638 WO2015171861A1 (en) 2014-05-07 2015-05-07 Humanized il-4 and il-4r alpha animals

Publications (1)

Publication Number Publication Date
SMT201800018T1 true SMT201800018T1 (it) 2018-03-08

Family

ID=53284509

Family Applications (2)

Application Number Title Priority Date Filing Date
SM20180018T SMT201800018T1 (it) 2014-05-07 2015-05-07 Animali umanizzati con il-4 e il4r alfa
SM20210560T SMT202100560T1 (it) 2014-05-07 2015-05-07 Animali il-4 e il -4r alfa umanizzati

Family Applications After (1)

Application Number Title Priority Date Filing Date
SM20210560T SMT202100560T1 (it) 2014-05-07 2015-05-07 Animali il-4 e il -4r alfa umanizzati

Country Status (26)

Country Link
US (7) US9565841B2 (enExample)
EP (3) EP3027015B1 (enExample)
JP (5) JP6640740B2 (enExample)
KR (2) KR102517112B1 (enExample)
CN (2) CN110269047B (enExample)
AU (3) AU2015255977B2 (enExample)
BR (1) BR112016025745A2 (enExample)
CA (2) CA3207834C (enExample)
CY (2) CY1119773T1 (enExample)
DK (2) DK3281521T3 (enExample)
ES (2) ES2887852T3 (enExample)
HR (2) HRP20211455T1 (enExample)
HU (2) HUE055860T2 (enExample)
IL (3) IL297105B2 (enExample)
LT (2) LT3027015T (enExample)
MX (1) MX370672B (enExample)
NO (1) NO2785538T3 (enExample)
PH (1) PH12016502058A1 (enExample)
PL (2) PL3281521T3 (enExample)
PT (2) PT3027015T (enExample)
RS (2) RS57073B1 (enExample)
RU (1) RU2703139C2 (enExample)
SG (2) SG10201912354PA (enExample)
SI (2) SI3027015T1 (enExample)
SM (2) SMT201800018T1 (enExample)
WO (1) WO2015171861A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2785538T3 (enExample) 2014-05-07 2018-08-04
RS60097B1 (sr) 2014-06-19 2020-05-29 Regeneron Pharma Ne-humane životinje koje imaju humanizovani gen za programiranu ćelijsku smrt 1
HUE061930T2 (hu) * 2014-09-17 2023-09-28 Oerlikon Surface Solutions Ag Pfaeffikon Eljárás javított kopásállóságú kétrétegû bevonatos vágószerszám elõállítására
RU2020122439A (ru) 2014-11-24 2020-09-24 Регенерон Фармасьютикалз, Инк. Не относящиеся к человеку животные, экспрессирующие гуманизированный комплекс cd3
CN107205368B (zh) 2014-12-05 2020-11-17 瑞泽恩制药公司 具有人源化分化簇47基因的非人动物
SMT202400313T1 (it) 2014-12-09 2024-09-16 Regeneron Pharma Animali non umani aventi un cluster umanizzato di un gene di differenziazione 274
RS61866B1 (sr) 2015-11-20 2021-06-30 Regeneron Pharma Ne-humane životinje koje imaju humanizovani gen za aktivaciju limfocita 3
JP6843872B2 (ja) 2016-02-04 2021-03-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 操作されたａｎｇｐｔｌ８遺伝子を有する非ヒト動物
RU2749715C2 (ru) * 2016-02-29 2021-06-16 Регенерон Фармасьютикалз, Инк. Грызуны, характеризующиеся гуманизированным геном tmprss
TWI784988B (zh) * 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
CA3059350A1 (en) 2017-04-13 2018-10-18 Regeneron Pharmaceuticals, Inc. Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1
US11248054B2 (en) 2017-06-12 2022-02-15 Bluefin Biomedicine, Inc. Anti-IL1RAP antibodies and antibody drug conjugates
WO2019067875A1 (en) 2017-09-29 2019-04-04 Regeneron Pharmaceuticals, Inc. NON-HUMAN ANIMALS COMPRISING A HUMANIZED TTR LOCUS AND METHODS OF USE
CN111655031B (zh) 2017-11-30 2022-11-18 瑞泽恩制药公司 包含人源化trkb基因座的非人动物
WO2019190990A1 (en) 2018-03-26 2019-10-03 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
IL277890B2 (en) 2018-04-11 2024-03-01 Regeneron Pharma Methods for quantifying il-33
JP7048051B2 (ja) 2018-07-11 2022-04-05 正徳 染井 痒みを軽減するアトピー性皮膚炎治療剤
PT3823443T (pt) 2018-07-16 2024-07-29 Regeneron Pharma Modelos de roedores da-doença ditra e as suas utilizações
CN111057721B (zh) * 2018-10-12 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化IL-4和/或IL-4Rα改造动物模型的制备方法及应用
CN111218425B (zh) * 2019-01-17 2022-02-08 百奥赛图(北京)医药科技股份有限公司 人源化转基因动物
EP3772929B1 (en) 2019-04-04 2023-11-15 Regeneron Pharmaceuticals, Inc. Rodents comprising a humanized coagulation factor 12 locus
JP7610339B2 (ja) 2019-06-04 2025-01-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ベータスリップ変異を有するヒト化ｔｔｒ遺伝子座を含む非ヒト動物と使用方法
TW202112229A (zh) 2019-06-07 2021-04-01 美商雷傑納榮製藥公司 包含人化白蛋白基因座之非人的動物
US20220272953A1 (en) * 2019-07-29 2022-09-01 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric il33
WO2021027737A1 (en) * 2019-08-09 2021-02-18 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric il2ra
WO2021093790A1 (en) * 2019-11-11 2021-05-20 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric genes
WO2021129766A1 (zh) * 2019-12-25 2021-07-01 江苏集萃药康生物科技股份有限公司 一种il-15人源化小鼠模型及其用途
KR20220133248A (ko) * 2020-01-28 2022-10-04 리제너론 파마슈티칼스 인코포레이티드 인간화 pnpla3 좌위를 포함하는 비-인간 동물 및 사용 방법
CN111149767B (zh) * 2020-02-24 2021-07-20 中南大学湘雅二医院 一种人源化皮肤型红斑狼疮小鼠模型的构建方法和应用
CN113527485B (zh) 2020-04-17 2024-11-15 湖南麦济生物技术股份有限公司 抗人白细胞介素-4受体α抗体及其制备方法和应用
CN111808882B (zh) * 2020-09-01 2020-12-29 北京百奥赛图基因生物技术有限公司 Il7r基因人源化改造的动物模型的构建方法及其应用
CN111793646B (zh) * 2020-09-08 2021-01-15 北京百奥赛图基因生物技术有限公司 Il1r1基因人源化改造的非人动物的构建方法及其应用
CN111926039B (zh) * 2020-09-23 2021-03-16 百奥赛图(北京)医药科技股份有限公司 Il-13基因人源化的非人动物的构建方法和应用
WO2022140221A1 (en) * 2020-12-21 2022-06-30 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized tslp gene, a humanized tslp receptor gene, and/or a humanized il7ra gene
WO2022247936A1 (en) * 2021-05-28 2022-12-01 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric cd36
WO2024067796A1 (zh) * 2022-09-28 2024-04-04 百奥赛图(北京)医药科技股份有限公司 一种il5和/或il5ra基因人源化修饰的非人动物
KR20250135248A (ko) * 2023-01-11 2025-09-12 리제너론 파아마슈티컬스, 인크. 규제 준수 자동화된 검정을 위한 시스템 및 방법
WO2025175099A1 (en) 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. A rodent copd model

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU643427B2 (en) * 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
PT1802193E (pt) 2004-10-19 2014-06-23 Regeneron Pharma Método para gerar um murganho homozigótico para uma modificação genética
JP2007252370A (ja) * 2006-02-22 2007-10-04 Institute Of Physical & Chemical Research Ｉｌ−４初期発現系トランスジェニック非ヒト動物およびその利用
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
US20110016543A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genomic editing of genes involved in inflammation
CN102725400A (zh) * 2009-06-29 2012-10-10 麻省理工学院 制造人源化的非人类哺乳动物的方法
SG177711A1 (en) * 2009-07-24 2012-02-28 Sigma Aldrich Co Llc Method for genome editing
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
EP4049535B1 (en) 2009-10-06 2024-11-27 Regeneron Pharmaceuticals, Inc. Genetically modified mice and engraftment
RU2730643C2 (ru) 2011-02-15 2020-08-24 Ридженерон Фармасьютикалз, Инк. Гуманизированные m-csf мыши
SG10201909638UA (en) 2011-10-28 2019-11-28 Regeneron Pharma Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules
DK3262932T3 (da) 2011-10-28 2019-08-05 Regeneron Pharma Genmodificerede mus med major histokompatibilitetskompleks
ES2624605T3 (es) * 2011-10-28 2017-07-17 Regeneron Pharmaceuticals, Inc. IL-6 y receptor de IL-6 humanizados
US8962913B2 (en) 2012-06-18 2015-02-24 Regeneron Pharmaceuticals, Inc. Humanized IL-7 rodents
PT4011915T (pt) * 2012-08-21 2024-01-02 Regeneron Pharma Métodos para o tratamento ou prevenção da asma através da administração de um antagonista de il-4r
JP6283031B2 (ja) 2012-09-07 2018-02-21 イエール ユニバーシティ 遺伝学的に修飾された非ヒト動物およびその使用法
EP3308641B1 (en) 2012-11-05 2019-07-03 Regeneron Pharmaceuticals, Inc. Immunodeficient, genetically modified rodent and methods of use thereof
CN111484999B (zh) 2013-02-20 2024-10-25 瑞泽恩制药公司 人源化的t细胞共受体的小鼠
US10154658B2 (en) 2013-02-22 2018-12-18 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
SMT201900067T1 (it) 2013-09-23 2019-02-28 Regeneron Pharma Animali non umani aventi un gene di proteina regolatoria del segnale umanizzato
HRP20170380T1 (hr) 2013-10-15 2017-05-19 Regeneron Pharmaceuticals, Inc. Životinje s humaniziranim il-5
CA2929774C (en) 2013-11-19 2020-09-15 Regeneron Pharmaceuticals, Inc. Non-human animal cells having a humanized proliferation-inducing ligand gene
ES2700972T3 (es) 2013-11-19 2019-02-20 Regeneron Pharma Animales no humanos que tienen un gen de factor activador de células B humanizado
SG10201908800YA (en) 2014-04-08 2019-11-28 Regeneron Pharma Non-human animals having humanized fc-gamma receptors
MA51519A (fr) 2014-05-05 2020-11-11 Regeneron Pharma Animaux c5 et c3 humanisés
NO2785538T3 (enExample) * 2014-05-07 2018-08-04

Also Published As

Publication number Publication date
AU2021218060B2 (en) 2024-04-11
NZ725615A (en) 2024-05-31
DK3281521T3 (da) 2021-09-20
US9743647B2 (en) 2017-08-29
SI3027015T1 (en) 2018-02-28
HUE038028T2 (hu) 2018-09-28
DK3027015T3 (en) 2018-01-22
US20230027494A1 (en) 2023-01-26
KR20160150637A (ko) 2016-12-30
EP3281521A1 (en) 2018-02-14
NO2785538T3 (enExample) 2018-08-04
IL304841B1 (en) 2025-09-01
IL297105B1 (en) 2023-09-01
IL297105B2 (en) 2024-01-01
HRP20211455T1 (hr) 2022-01-07
JP2017514501A (ja) 2017-06-08
JP2020058379A (ja) 2020-04-16
CA2947307C (en) 2023-09-26
SMT202100560T1 (it) 2021-11-12
IL297105A (en) 2022-12-01
AU2021218060C1 (en) 2024-11-07
BR112016025745A2 (pt) 2018-01-16
JP2024159985A (ja) 2024-11-08
AU2021218060A1 (en) 2021-09-09
RU2016143376A (ru) 2018-06-09
CY1119773T1 (el) 2018-06-27
US12310340B2 (en) 2025-05-27
HUE055860T2 (hu) 2021-12-28
JP7755699B2 (ja) 2025-10-16
SG10201912354PA (en) 2020-02-27
RS57073B1 (sr) 2018-06-29
JP7145250B2 (ja) 2022-09-30
JP2021087434A (ja) 2021-06-10
KR20220165814A (ko) 2022-12-15
US20200022344A1 (en) 2020-01-23
AU2024204694A1 (en) 2024-09-05
EP3281521B1 (en) 2021-06-30
AU2015255977A1 (en) 2016-11-17
CN106470545B (zh) 2019-08-20
US20150320021A1 (en) 2015-11-12
PL3281521T3 (pl) 2022-01-03
US20170311580A1 (en) 2017-11-02
NZ763861A (en) 2024-05-31
IL248358B2 (en) 2023-03-01
RS62345B1 (sr) 2021-10-29
IL304841A (en) 2023-09-01
US10588298B2 (en) 2020-03-17
IL248358A0 (en) 2016-11-30
IL248358B (en) 2022-11-01
HRP20180242T1 (hr) 2018-03-09
RU2016143376A3 (enExample) 2018-11-22
CA2947307A1 (en) 2015-11-12
EP3027015B1 (en) 2017-11-08
KR102473565B1 (ko) 2022-12-02
CY1124605T1 (el) 2022-07-22
JP6838131B2 (ja) 2021-03-03
US9565841B2 (en) 2017-02-14
CN106470545A (zh) 2017-03-01
LT3027015T (lt) 2018-01-25
PL3027015T3 (pl) 2018-04-30
IL304841B2 (en) 2026-01-01
SG11201608570YA (en) 2016-11-29
ES2887852T3 (es) 2021-12-28
CN110269047B (zh) 2021-11-02
US10477842B2 (en) 2019-11-19
US11109578B2 (en) 2021-09-07
RU2019131253A (ru) 2019-12-06
CA3207834C (en) 2025-10-14
SI3281521T1 (sl) 2021-11-30
JP6640740B2 (ja) 2020-02-05
CN110269047A (zh) 2019-09-24
MX2016014563A (es) 2017-02-23
WO2015171861A1 (en) 2015-11-12
EP3906781A1 (en) 2021-11-10
US11963521B2 (en) 2024-04-23
ES2656529T3 (es) 2018-02-27
PT3027015T (pt) 2018-02-09
EP3027015A1 (en) 2016-06-08
US20150320022A1 (en) 2015-11-12
PH12016502058A1 (en) 2017-01-09
PT3281521T (pt) 2021-09-16
MX370672B (es) 2019-12-19
RU2703139C2 (ru) 2019-10-15
US20180000056A1 (en) 2018-01-04
CA3207834A1 (en) 2015-11-12
JP2022171841A (ja) 2022-11-11
US20210368753A1 (en) 2021-12-02
KR102517112B1 (ko) 2023-04-03
LT3281521T (lt) 2021-09-27
AU2015255977B2 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
IL297105B1 (en) Animals with il–4 and il–4r alpha of human origin
IL276946A (en) Antiproliferative compounds and methods of use
IL248481B (en) Animals containing c5 and c3 of human origin
IL252216B (en) Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines
IL252929A0 (en) Anti-acth antibodies from humans and their use
GB201401617D0 (en) Novel combination and use
IL247315B (en) Anti-acth antibodies and their uses
SI3233105T1 (sl) Nove kombinacije in uporaba
IL251335A0 (en) Piperidinylpyrazolopyrimidinones and their use
GB201420805D0 (en) Ligatures and use thereof
PL3229772T3 (pl) 6-arylo-9-glikozylopuryny i ich zastosowanie